HRD Test, BRACAnalysis Predict Platinum-based Treatment Benefit in Early-Stage, Advanced TNBC | GenomeWeb

SAN ANTONIO – Using Myriad Genetics' next-generation sequencing based homologous recombination deficiency (HRD) Test, researchers have identified a subset of early-stage triple-negative breast cancer (TNBC) patients who responded to platinum-based therapies, according to data presented at the San Antonio Breast Cancer Symposium.

Additionally, in a separate study presented here, this time in advanced TNBC patients, researchers reported that BRCA mutation status gauged by Myriad's BRACAnalysis test was predictive of carboplatin benefit over docetaxel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.